Viridian Therapeutics: Advancing TED Pipeline, 2026 Catalysts, and New TSH Receptor Inhibitor Underpin Buy Rating

LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VRDN stock, giving a Buy rating today.

Rami Katkhuda has given his Buy rating due to a combination of factors tied to Viridian Therapeutics’ advancing pipeline and upcoming catalysts in 2026. He highlights the company’s newly unveiled TSH receptor inhibitor, engineered for subcutaneous delivery via autoinjector and designed with an extended half-life that could allow less frequent dosing, as a strategically important addition in Graves’ disease and thyroid eye disease (TED). In his view, this mechanism directly targets the autoimmune driver of these conditions and meaningfully broadens Viridian’s long-term growth opportunity.

Rami also bases his positive stance on the regulatory and commercial momentum of veligrotug in TED, emphasizing that the FDA’s Priority Review and June 30, 2026 PDUFA date, along with an upcoming EMA filing, position the asset well for a near-term launch. He underscores that the pivotal THRIVE dataset supports clear differentiation from the current standard of care, including quicker clinical benefit, strong efficacy in chronic TED (particularly on diplopia), and a more convenient infusion profile, which together should enable robust uptake among the ~2,000 core TED prescribers. Finally, he notes that pivotal REVEAL-1 and REVEAL-2 readouts for subcutaneous elegrobart (VRDN-003) expected in the first half of 2026 provide additional upside optionality, reinforcing his conviction that Viridian is entering a high-impact period that justifies a Buy rating.

In another report released today, Needham also maintained a Buy rating on the stock with a $42.00 price target.